Psilocybin's lasting benefits prove elusive in mice

Five Bay Area laboratories undertook a collaborative effort to test whether psilocybin produces lasting effects on anxiety and depression-like behavior in mice, according to a STAT News report published November 2. The multi-lab design was intended to address a persistent problem in psychedelic research: results from single laboratories that fail to replicate elsewhere.

The report states that the collaboration found limited evidence for durable benefits from psilocybin in the mouse models tested. STAT News did not describe a single, consistent positive effect emerging across the five labs’ combined data.

The story notes that psilocybin has drawn significant investment and attention as a potential treatment for depression and anxiety disorders, with proponents pointing to its capacity to produce lasting psychological change after limited dosing. The mouse study was structured specifically to probe whether that durability holds up under coordinated, cross-laboratory scrutiny rather than relying on findings from any single research group.

STAT News frames the result as a tempering data point for a field that has seen considerable enthusiasm and funding directed toward psychedelic compounds as therapeutic agents. The report does not claim the findings rule out benefits in humans, and it does not describe the specific behavioral assays, dosing protocols, or statistical methods used by the five laboratories in sufficient detail to be summarized here.

The study’s authors and institutional affiliations were not specified in the available excerpt.